"We are excited to establish the agreement with GSK, a global biopharma company. It reflects the growing recognition of our R&D capabilities. This agreement will solidify a robust foundation for ...

GSK (LSE:GSK) has licensed worldwide rights to its experimental liver disease drug linerixibat to Alfasigma. The agreement covers development and commercialization of linerixibat as GSK reallocates ...

Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...

GSK (GSK) stock is in focus as the company inks a drug licensing deal worth up to $1B with China's Frontier Biotechnologies for siRNA treatments. Read more here.

GSK and CureVac forged their relationship during the Covid-19 pandemic, setting out to develop messenger RNA vaccines that could protect against the novel coronavirus and other infectious diseases.

Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseasesHS235 offers potential to treat pulmonary ...

GSK said it is ending the development program for the small-molecule drug Belrestotug. The British pharmaceutical giant said Tuesday that the decision is based on a new interim analyses from phase 2 ...

Feb 25 (Reuters) - GSK has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking ...

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks for a new generation of immunotherapy medicines. Interim analysis from two ...

The collaboration will combine 23andMe’s large-scale genetic resources and advanced data science skills, with GSK’s scientific and medical knowledge and commercialization expertise. The goal is to ...